NDLI: Does the development of new medicinal products in the European Union address global and regional health concerns?

Please wait, while we are loading the content...

Socioeconomic disparities in self-reported cardiovascular disease for Indigenous and non-Indigenous Australian adults: analysis of national survey data

Measuring the health of the Indian elderly: evidence from National Sample Survey data

Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence

Psychosocial stress and strategies for managing adversity: measuring population resilience in New South Wales, Australia

Deaths of infants subject to forensic autopsy in Estonia from 2001 to 2005: what can we learn from additional information?

A novel framework for validating and applying standardized small area measurement strategies

Correlating pharmaceutical data with a national health survey as a proxy for estimating rural population health

A comparison of physicians and medical assistants in interpreting verbal autopsy interviews for allocating cause of neonatal death in Matlab, Bangladesh: can medical assistants be considered an alternative to physicians?

Schizophrenia in Thailand: prevalence and burden of disease

The effect of participant nonresponse on HIV prevalence estimates in a population-based survey in two informal settlements in Nairobi city

Verbal autopsy interpretation: a comparative analysis of the InterVA model versus physician review in determining causes of death in the Nairobi DSS

Consistency and precision of cancer reporting in a multiwave national panel survey

Designing verbal autopsy studies

A set of indicators for decomposing the secular increase of life expectancy

Thermal discomfort with cold extremities in relation to age, gender, and body mass index in a random sample of a Swiss urban population

Estimating prevalence of overweight and obesity at the neighborhood level: the value of maternal height and weight data available on birth certificate records

Early mortality experience in a large military cohort and a comparison of mortality data sources

Cause-of-death ascertainment for deaths that occur outside hospitals in Thailand: application of verbal autopsy methods

Cause-specific mortality patterns among hospital deaths in Thailand: validating routine death certification

Estimated causes of death in Thailand, 2005: implications for health policy

Integrated multisource estimates of mortality for Thailand in 2005

Verifying causes of death in Thailand: rationale and methods for empirical investigation

Algorithms for enhancing public health utility of national causes-of-death data

Comparing population health in the United States and Canada

Analysis of five-year trends in self-reported language preference and issues of item non-response among Hispanic persons in a large cross-sectional health survey: implications for the measurement of an ethnic minority population

Deaths from heart failure: using coarsened exact matching to correct cause-of-death statistics

The United States of America and the Islamic Republic of Iran: the path to preventing traffic injuries?

The burden of injuries in Iranian children in 2005

Statistical modeling of volume of alcohol exposure for epidemiological studies of population health: the US example

Using breath carbon monoxide to validate self-reported tobacco smoking in remote Australian Indigenous communities

The Summary Index of Malaria Surveillance (SIMS): a stable index of malaria within India

Does the development of new medicinal products in the European Union address global and regional health concerns?

Content Provider	Springer Nature : BioMed Central
Author	Catalá-López,, Ferrán García-Altés,, Anna Álvarez-Martín, Elena Gènova-Maleras, Ricard Morant-Ginestar, Consuelo
Abstract	Background Since 1995, approval for many new medicinal products has been obtained through a centralized procedure in the European Union. In recent years, the use of summary measures of population health has become widespread. We investigated whether efforts to develop innovative medicines are focusing on the most relevant conditions from a global public health perspective. Methods We reviewed the information on new medicinal products approved by centralized procedure from 1995 to 2009, information that is available to the public in the European Commission Register of medicinal products and the European Public Assessment Reports from the European Medicines Agency. Morbidity and mortality data were included for each disease group, according to the Global Burden of Disease project. We evaluated the association between authorized medicinal products and burden of disease measures based on disability-adjusted life years (DALYs) in the European Union and worldwide. Results We considered 520 marketing authorizations for medicinal products and 338 active ingredients. New authorizations were seen to increase over the period analyzed. There was a positive, high correlation between DALYs and new medicinal product development (ρ = 0.619, p = 0.005) in the European Union, and a moderate correlation for middle-low-income countries (ρ = 0.497, p = 0.030) and worldwide (ρ = 0.490, p = 0.033). The most neglected conditions at the European level (based on their attributable health losses) were neuropsychiatric diseases, cardiovascular diseases, respiratory diseases, sense organ conditions, and digestive diseases, while globally, they were perinatal conditions, respiratory infections, sense organ conditions, respiratory diseases, and digestive diseases. Conclusions We find that the development of new medicinal products is higher for some diseases than others. Pharmaceutical industry leaders and policymakers are invited to consider the implications of this imbalance by establishing work plans that allow for the setting of future priorities from a public health perspective.
Related Links	https://pophealthmetrics.biomedcentral.com/counter/pdf/10.1186/1478-7954-8-34.pdf
Ending Page	10
Page Count	10
Starting Page	1
File Format	HTM / HTML
ISSN	14787954
DOI	10.1186/1478-7954-8-34
Journal	Population Health Metrics
Issue Number	1
Volume Number	8
Language	English
Publisher	BioMed Central
Publisher Date	2010-12-20
Access Restriction	Open
Subject Keyword	Public Health Epidemiology Research Methodology Health Services Research European Union Medicinal Product European Medicine Agency Marketing Authorization Centralize Procedure
Content Type	Text
Resource Type	Article
Subject	Public Health, Environmental and Occupational Health Epidemiology
Journal Impact Factor	3.2/2023
5-Year Journal Impact Factor	3.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Does the development of new medicinal products in the European Union address global and regional health concerns?

New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.

Evaluation of data availability on population health indicators at the regional level across the European Union

Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021

Public health in the new European Union research programme.

Early access to medicinal products: potential and limits

Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products.

Changes to the European Union pharmaceutical legislation: Implications of the ‘Pharma Review’ for biotechnology companies

The european paediatric legislation: benefits and perspectives

Does the development of new medicinal products in the European Union address global and regional health concerns?

Similar Documents

Does the development of new medicinal products in the European Union address global and regional health concerns?

New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.

Evaluation of data availability on population health indicators at the regional level across the European Union

Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021

Public health in the new European Union research programme.

Early access to medicinal products: potential and limits

Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products.

Changes to the European Union pharmaceutical legislation: Implications of the ‘Pharma Review’ for biotechnology companies

The european paediatric legislation: benefits and perspectives

Does the development of new medicinal products in the European Union address global and regional health concerns?